Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept Reversing Subclinical Inflammation in ACPA Positive Arthralgia (ARIAA)
NCT02778906Phase 3Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Nov 2014
- Primary completion
- Dec 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) and arthralgia comparing Abatacept with Placebo (2 arms). Primary endpoint: Proportion of patients with an improvement of acute inflammation (synovitis or osteitis) in the MRI of the dominant hand at 6 months. Started Nov 2014; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)arthralgia
Beyond the preview
Go deeper on NCT02778906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02778906.